<DOC>
	<DOCNO>NCT01467492</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety telaprevir combination pegylated interferon alfa 2a ( Peg-IFN-alfa-2a ) ribavirin ( RBV ) treatment-experienced Black/African American non-Black/African American participant Genotype 1 Chronic Hepatitis C ( CHC ) , achieve sustained viral response prior course interferon-based therapy .</brief_summary>
	<brief_title>Telaprevir , Peg-IFN-alfa-2a , RBV Treatment-Experienced Black/African American Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description>This single-arm , open-label , multicenter study treatment-experienced participant Genotype 1 CHC , self-identified Black/African American ( Group A ) self-identify Black/African American ( Group B ) . Participants achieve sustain virologic response 24 week least 1 prior course Peg-IFN-alfa-2a/RBV therapy standard duration , 1 follow viral response : - Prior relapse : Participant document undetectable hepatitis C virus ribonucleic acid ( HCV RNA ) level planned end treatment least 42 week duration ( HCV RNA evaluate anytime 3 week 6 week last dose Peg IFN-alfa-2a RBV ) . - Prior null response : Participant &lt; 2-log10 decrease HCV RNA 12 week , prior Peg IFN-alfa-2a/RBV treatment , never achieve undetectable HCV RNA treatment . - Prior partial response : Participant &gt; =2-log10 decrease HCV RNA 12 week , prior Peg IFN-alfa-2a/RBV treatment , never achieve undetectable HCV RNA treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participants selfidentify Black/African American ( Group A ) selfidentify Black/African American ( Group B ) Participants Genotype 1 CHC laboratory evidence hepatitis C virus ( HCV ) infection least 6 month Participants achieve sustain viral response 24 week last dose study drug ( SVR24 ) , least 1 prior course PegIFNalfa2a/RBV therapy standard duration Participants receive previous treatment telaprevir protease inhibitor ( ) CHC Participants evidence hepatic decompensation Participants diagnose suspected hepatocellular carcinoma Participants cause significant liver disease addition HCV Participants currently abuse illicit drug alcohol , history illicit substance alcohol abuse within 2 year screen visit Participants participate investigational drug study within 90 day dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>VX-950 , Incivek</keyword>
</DOC>